Clinical Trial

A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 9, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase I, open-label, two-part, fixed-sequence drug interaction study conducted to evaluate the effects of concomitant use of the potent CYP3A4 inhibitor itraconazole or the CYP3A4 inducer rifampin on the pharmacokinetics of Rocbrutinib in healthy subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-24.
Status change: Not Yet Recruiting → Recruiting 2026-03-06
Trial Details
NCT Number NCT07374224
Lead Sponsor Guangzhou Lupeng Pharmaceutical Company LTD.
Conditions Clinical Pharmacology
Enrollment 28 participants
Start Date 2026-03-05
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-09